**CLAIMS**

1. A pharmaceutically acceptable composition having a pH of about 9.1 to about 9.8 at 25°C, comprising:

active components comprising carbidopa and at least about 4% by weight levodopa;

arginine and optionally meglumine,

preferably wherein said composition comprises (i) about 4% to about 12%, or about 5% to about 30%, by weight levodopa; or (ii) about 1% to about 6%, or about 1% to about 2%, by weight carbidopa; or (iii) about 10% to about 35% by weight arginine.

2. The pharmaceutically acceptable composition of claim 1, wherein the molar ratio of active components to the arginine is about 1:1.8 to about 1:3.5, or about 1:2.3.

~~3. The pharmaceutically acceptable composition of claim 1 or 2, comprising about 4% to about 12%, or about 5% to about 30%, by weight levodopa.~~

~~4. The pharmaceutically acceptable composition of any one of claims 1-3, comprising about 1% to about 6%, or about 1% to about 2%, by weight carbidopa.~~

3 ~~5~~. The pharmaceutically acceptable composition of any one of claims ~~1-4~~ 1-2, comprising meglumine, preferably wherein the molar ratio of active components to the arginine is about 1:1.1 to about 1:1.9, and the molar ratio of active components to the meglumine is about 1:0.3 to about 1:1.5.

~~6. The pharmaceutically acceptable composition of claim 5, wherein the molar ratio of active components to the arginine is about 1:1.1 to about 1:1.9, and the molar ratio of active components to the meglumine is about 1:0.3 to about 1:1.5.~~

4 ~~7~~. The pharmaceutically acceptable composition of claim ~~5 or 6~~ 3, wherein the molar ratio of active components to the meglumine is about 1:0.3 to about 1:1.2, about 1:0.4, or about 1:1.1.

5 ~~8~~. The pharmaceutically acceptable composition of ~~any one of claims 5-7~~ claim 3 or 4, wherein the composition comprises about 2.0% to about 11% by weight meglumine.

~~9. The pharmaceutically acceptable composition of any one of claims 1-8, comprising about 10% to about 35% by weight arginine.~~

6 ~~10~~. The pharmaceutically acceptable composition of any one of claims ~~1-9~~ 1-5, further comprising an agent that inhibits the formation of oxidation products, preferably wherein said agent is selected from ascorbic acid or a pharmaceutically acceptable salt thereof, Na-ascorbate, L-cysteine, N-acetylcysteine (NAC), gluthatione (GSH), $Na_2$-EDTA, $Na_2$-EDTA-Ca, sodium bisulfite, or combinations thereof.

~~11. The pharmaceutically acceptable composition of claim 10, wherein the agent is selected from ascorbic acid, Na-ascorbate, L-cysteine, N-acetylcysteine (NAC), gluthatione (GSH), $Na_2$-EDTA, $Na_2$-EDTA-Ca, or combinations thereof.~~

~~12. The pharmaceutically acceptable composition of claim 10, wherein said agent is ascorbic acid or a pharmaceutically acceptable salt thereof.~~

~~13. The pharmaceutically acceptable composition of any one of claims 1-12, further comprising sodium bisulfite.~~

7 ~~14~~. A pharmaceutically acceptable composition comprising levodopa, arginine and optionally meglumine; and further comprising ascorbic acid or a pharmaceutically acceptable salt thereof, preferably wherein said composition comprises about 0.25% or more, about 0.2% to about 3%, or about 0.5% to about 1%, by weight ascorbic acid or a pharmaceutically acceptable salt thereof such as ascorbate, sodium ascorbate, calcium ascorbate, potassium ascorbate, ascorbyl palmitate, or ascorbyl stearate, preferably sodium ascorbate.

~~15. The pharmaceutically acceptable composition of claim 14, wherein the ascorbic acid salt is selected from ascorbate, sodium ascorbate, calcium ascorbate, potassium ascorbate, ascorbyl palmitate, or ascorbyl stearate, preferably sodium ascorbate.~~

~~16. The pharmaceutically acceptable composition of claim 14, comprising about 0.25% or more, about 0.2% to about 3%, or about 0.5% to about 1%, by weight ascorbic acid or a pharmaceutically acceptable salt thereof.~~

8 ~~17~~. The pharmaceutically acceptable composition of ~~any one of claims 14-16~~ claim 7, wherein the molar ratio of levodopa to the arginine is about 1:1.8 to about 1:3.5, or about 1:2.3, preferably wherein said composition comprises about 4% to about 12% by weight levodopa.

~~18. The pharmaceutically acceptable composition of claim 17, comprising about 4% to about 12% by weight levodopa.~~

9 ~~19~~. The pharmaceutically acceptable composition of ~~any one of claims 14-17~~ claim 7 or 8, further comprising carbidopa, preferably about 1% to about 2% by weight carbidopa.

~~20. The pharmaceutically acceptable composition of claim 19, comprising about 1% to about 2% by weight carbidopa.~~

10 ~~21~~. The pharmaceutically acceptable composition of claim ~~19 or 20~~ 9, wherein the molar ratio of the levodopa and the carbidopa together, to the arginine, is about 1:1.8 to about 1:3.5, or about 1:2.3.

11 ~~22~~. The pharmaceutically acceptable composition of ~~any one of claims 19-21~~ claim 9 or 10, wherein the composition has a pH of about 9.1 to about 9.8 at 25°C.

12 ~~23~~. The pharmaceutically acceptable composition of any one of claims ~~1-22~~ 1-11, wherein the formulation is liquid at room temperature.

13 ~~24~~. The pharmaceutically acceptable composition of any one of claims ~~1-23~~ 1-12, further comprising entacapone or tolcapone.

~~25. The pharmaceutically acceptable formulation of any one of claims 1-24, wherein the formulation is stable for at least two weeks at 25°C±5°C, or for at least two months at -20°C±5°C.~~

14 ~~26~~. A transdermal patch suitable for administering a pharmaceutically acceptable composition according to any one of claims ~~1-25~~ 1-13.

15 ~~27~~. ~~A method of~~ Use of the pharmaceutically acceptable composition of any one of claims 1-13 for the preparation of a medicament for treatment of ~~treating~~ a neurological or movement disorder such as Parkinson's disease ~~in a patient in need thereof, comprising administering to said patient a composition of any one of claims 1-25~~.

~~28. The method of claim 27, further comprising orally administering levodopa and/or carbidopa and optionally entacapone or tolcapone.~~

16 ~~29~~. The ~~method~~ use of claim ~~27~~ 15, wherein the ~~composition~~ medicament is ~~administered~~ formulated for subcutaneous~~ly~~, transdermal, intraduodenal~~ly~~ or intravenous~~ly~~ administration.

~~30. The method of claim 27, wherein the composition is administered substantially continuously.~~

~~31. The method of claim 30, wherein the composition is administered subcutaneously using one or more infusion pumps and/or transdermal and/or dermal patches.~~

~~32. The method of claim 30 or 31, wherein the rate of administering the composition is at least about 0.01 ml/hour to about 0.2 ml/h, at least about 0.07 ml/hour, or about 0.15 ml/hour during the day or during patient activity, and about 0 to about 0.075 0.25 ml/hour.~~

~~33. The method of claim 30 or 31, wherein the rate of administering the composition is about 0.20 ml/hour to about 2.0 ml/h, about 1.0 ±0.5 ml/hour, or about 1.25 ±0.5 ml/hour during the day or during patient activity, and about 0 to about 0.5 ml/hour at night or at rest.~~

~~34. The method of any one of claims 27-33, wherein the disorder is Parkinson's disease.~~

17 ~~35~~. A pharmaceutically acceptable formulation comprising about 2.5 to about 7% by weight levodopa, about 0 to about 2% by weight carbidopa, about 5 to about 18% by

weight arginine, and about 0.25% to about 3% by weight ascorbic acid or a pharmaceutically acceptable salt thereof.

18 ~~36~~. A pharmaceutically acceptable formulation comprising (i) about 8 to about 12% by weight levodopa, about 1 to about 3% by weight carbidopa, and about 15 to about 35% weight arginine; or (ii) about 8 to about 12% by weight levodopa, about 1 to about 3% by weight carbidopa, about 12 to about 15% weight arginine, and about 3% to about 10% by weight meglumine, wherein said pharmaceutically acceptable formulation optionally further comprising about 0.25-3% by weight ascorbic acid.

~~37. The pharmaceutically acceptable formulation of claim 36, further comprising about 0.25-3% by weight ascorbic acid.~~

19 ~~38~~. A pharmaceutically acceptable liquid composition comprising arginine and entacapone or tolcapone, preferably wherein said composition comprises at least about 2%, at least about 4%, or at least about 2% to about 12%, by weight entacapone or tolcapone.

~~39. The pharmaceutically acceptable liquid composition of claim 38, comprising at least about 2%, at least about 4%, or at least about 2% to about 12%, by weight entacapone or tolcapone.~~

20 ~~40~~. The pharmaceutically acceptable liquid composition of claim ~~38 or 39~~ 19, wherein the entacapone or tolcapone and the arginine have a molar ratio of about 1:0.5 to about 1:2.5, or about 1:1 to about 1:1.5.

21 ~~41~~. The pharmaceutically acceptable liquid composition of claim ~~38~~ 19, wherein the pH of the liquid composition is about 6 to about 9 at 25°C, or the liquid composition is substantially stable at 25°C for 48 hours or more.

~~42. The pharmaceutically acceptable liquid composition of any one of claims 38-41, further comprising a pharmaceutically acceptable excipient.~~

22 ~~43~~. The pharmaceutically acceptable formulation of any one of claims ~~36-42~~ 18-21, wherein said formulation is suitable for substantially continuous subcutaneous, intraduodenal or intravenous administration.

23 ~~44~~. A process for preparing a stable liquid solution comprising levodopa and/or carbidopa, and arginine, comprising:

providing levodopa and/or carbidopa, and arginine to form a powder mixture;

adding water to said powder mixture to form a suspension;

heating said suspension at a temperature of about 40°C to about 90°C to form a solution; and

cooling said solution to provide the stable liquid composition.

~~45. The process of claim 44, wherein heating said suspension further comprises stirring the suspension.~~

24 ~~46~~. A pharmaceutically acceptable composition comprising (i) carbidopa, at least 4% by weight levodopa, arginine and optionally meglumine; or (ii) levodopa, arginine, optionally meglumine, and ascorbic acid or a pharmaceutically acceptable salt thereof, for use in treatment of a neurological or movement disorder such as Parkinson's disease.

~~47. The pharmaceutically acceptable composition of claim 46, wherein said neurological or movement disorder is Parkinson's disease.~~